Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma

• Published in: The journal of allergy and clinical immunology in practice (Cambridge, MA) Vol. 10; no. 7; pp. 1935 - 1936
• Main Authors: Yılmaz, İnsu, Çetin, Gülden Paçacı, Arslan, Bahar
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Limited 01-07-2022
• Subjects: Asthma; Biological products; Comorbidity; Immunotherapy; Interleukin 5; Interleukin 5 receptors; Leukocytes (eosinophilic); Monoclonal antibodies; Otitis; Patients; Polyposis; Rhinoconjunctivitis; Rhinosinusitis
• ISSN: 2213-2198; 2213-2201
• DOI: 10.1016/j.jaip.2022.04.017

First of all, we think that the criteria for the definition of super-responder are debatable. Another point that draws our attention is that after 2 years of treatment in the super-responder group, it was stated in Table I that comorbidities of chronic rhinosinusitis, nasal polyposis (NP), chronic otitis, and allergic rhinoconjunctivitis were under control with these biologics; however, the control criteria were not defined in this article. [...]some studies have shown that the presence of comorbid NP predicts that severe asthma may respond well to anti-IL5/IL5R monoclonal antibodies.2-5 In addition, in the Global Initiative for Asthma report, NP is included in the criteria for good response to anti-IL5/IL5R in patients with eosinophilic severe asthma.6 Finally, the authors also stated that anti-IL5/IL5R was discontinued in 3 patients because of adverse effects.